U.S. Court of Appeals rules that the PTAB applied the wrong legal standard for conception in the CRISPR-Cas9 interference dispute with the Broad Institute.  Decision sent back to the PTAB for reconsideration under the correct legal standard for assessing the inventor of CRISPR-Cas9 gene editing in eukaryotic cells.    Dublin,.

We stand at the forefront of a pivotal moment in human innovation—where AI and CRISPR gene editing converge to power what can only be described as the 21st century’s biological revolution.  A New Industrial Epoch  Just as coal and steam powered the 19th-century Industrial Revolution and electricity and chemistry fuelled.

Making CRISPR more accessible for scientific innovation   At ERS Genomics, we make CRISPR/Cas9 accessible to innovators. By licensing the foundational IP co-owned by Professor Emmanuelle Charpentier, we enable a broad spectrum of applications outside of direct therapeutic use—from drug discovery to innovation in fields far beyond pharma. One of.